• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight

    4/7/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    New HemoSphere Stream™ Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients.

    FRANKLIN LAKES, N.J. , April 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the HemoSphere Stream™ Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close gaps between intermittent readings. 

    New HemoSphere Stream™ Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients.

    "We're delivering real-time visibility of hemodynamic changes to more patients and care settings by making continuous, noninvasive monitoring available on compatible multiparameter monitors." said Tim Patz, worldwide president of Advanced Patient Monitoring at BD. "Patients who may not require an invasive arterial line can now benefit from continuous blood pressure monitoring, rather than intermittent checks."  

    The compact HemoSphere Stream™ Module mounts easily to an IV pole, taking no additional footprint in clinical environments. When used with the VitaWave™ Plus Finger Cuff, the HemoSphere Stream™ Module serves as the interface that delivers continuous, noninvasive arterial blood pressure waveform data to compatible multiparameter monitors. Together with the finger cuff and supporting accessories, it comprises the VitaWave™ Plus System, which is designed for accuracy using technology validated against arterial line measurements.  

    "Monitoring blood pressure and perfusion during and after surgery is key to reducing major complications after surgery. Anesthesia providers have been waiting for the availability of a simple way to measure continuous blood pressure noninvasively. This is a landmark technology to improve global patient safety," said Michael Scott, MD, Chair APSF Clinical Deterioration Committee.

    Continuous blood pressure helps reveal hemodynamic changes that may occur between intermittent blood pressure checks, which are typically taken every 3–5 minutes in the operating room. By providing a real-time view into blood pressure trends on any compatible patient monitor, the VitaWave™ Plus System supports the Anesthesia Patient Safety Foundation's (APSF) recommendations for continuous noninvasive hemodynamic monitoring to detect and treat intraoperative hypotension sooner. 

    Visit www.bd.com/HemoSphereStream for more information about BD's Advanced Patient Monitoring solutions including HemoSphere Stream™ Module and VitaWave™ Plus System.

    About BD

    BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X  @BDandCo or Instagram @becton_dickinson.

    Contacts:



    Media

    Investors

    Matt Marcus

    VP, Public Relations

    [email protected]        

    Shawn Bevec

    SVP, Investor Relations

    [email protected]  

    CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician.

    See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

    © 2026 BD. All Rights Reserved. BD, the BD Logo, HemoSphere, HemoSphere Stream, VitaWave and VitaWave Plus are trademarks of Becton, Dickinson and Company or its affiliates. BD-171978

     

    BD (Becton, Dickinson and Company) Logo (PRNewsfoto/BD (Becton, Dickinson and Company))

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/when-every-beat-matters-bd-helps-clinicians-eliminate-blind-spots-with-continuous-noninvasive-blood-pressure-insight-302734878.html

    SOURCE BD (Becton, Dickinson and Company)

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Neal Shana Carol

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    4/6/26 5:28:51 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Feld Michael

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    3/27/26 1:49:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    EVP and General Counsel Minnix Lanesha was granted 7,492 shares (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    3/17/26 2:46:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight

    New HemoSphere Stream™ Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients.FRANKLIN LAKES, N.J. , April 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the HemoSphere Stream™ Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinician

    4/7/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Launches AI-Enabled Medication Dispensing System to the European Market

    Advanced automation and connected data capabilities strengthen medication inventory control and enhance safety across pharmacy settings.FRANKLIN LAKES, N.J., April 1, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe. This next-generation medication dispensing system combines advanced automation and AI‑driven insights to modernize medication management, reduce disruptions, and improve efficiency while helping clinicians spend more time on patient care.

    4/1/26 5:00:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Pioneers New Standard in Surgical Safety with FDA-Cleared Surgiphor™ 1000mL for Wound Irrigation

    The first and only innovation of its kind to receive 510(k) clearance, Surgiphor™ 1000mL empowers surgical teams with a consistent, antimicrobial solution designed to improve patient care and operating room (OR) efficiencyFRANKLIN LAKES, N.J., March 2, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Surgiphor™ 1000mL. As the first and only 1000 mL antimicrobial irrigation system specifically designed for powered lavage, Surgiphor™ 1000mL provides a standardized, OR-ready solution that enhances surgical safety and efficacy.

    3/2/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    4/2/26 4:18:23 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/25/26 4:25:34 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/10/26 4:16:23 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Becton Dickinson with a new price target

    Citigroup resumed coverage of Becton Dickinson with a rating of Buy and set a new price target of $233.00

    2/3/26 6:55:14 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

    FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share. The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations pr

    1/27/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials